Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Objective: Although atypical antipsychotic drugs (AAPDs) have been found effective in the
augmentation of serotonin reuptake inhibitors (SRIs) for treatment-resistant
obsessive-compulsive disorder (OCD) in short terms trials, there are few data on the
effectiveness and safety of these agents in clinical settings over the long term.
Method: Subjects (n=46) who responded to selective SRIs (SSRIs) in an initial 12-week trial
were continued on SRI-monotherapy plus cognitive-behavioral therapy (CBT) for one year.
Subjects (n=44) who failed to respond to SSRIs were randomly assigned to one of 3 AAPDs such
as risperidone and were consecutively treated using SSRI+AAPD combined with CBT for a year.